find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
23
Clinical Trials
Leukemia
Phase III
Enrolling
nct/study# NCT05949684 / CA056-025
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD)
Learn More
Leukemia
N/A
Enrolling
nct/study# N/A / 2019-0544
Retrospective Chart Review, Leukemia, PI: Dr. McCloskey, Protocol Title: Efficacy of liposomal cytarabine/daunorubicin in secondary AML patients compared to idarubicin-containing 7+3 induction therapy.
Learn More
Leukemia
Phase III
Enrolling
nct/study# NCT06578247 / AC220-168
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY AND ADMINISTERED AS MAINTENANCE THERAPY IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD (-) ACUTE MYELOID LEUKEMIA (QUANTUM-WT) (QUIZARTINIB OR PLACEBO PLUS CHEMOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD (-) AML)
Learn More
Leukemia
Phase II/III
Enrolling
nct/study# NCT04256317 / ASTX030-01
A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Learn More
Leukemia
Phase I
Enrolling
nct/study# NCT04176198 / BBI-TP-3654-102
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
Learn More
Leukemia
N/A
Enrolling
nct/study# N/A / BLINCYTO-DLI-ALLOSCT
Assessing Survival Outcomes of Blinatumomab Therapy Following Donor Lymphocyte Infusion and Allogeneic Stem Cell Transplant in Acute Lymphoblastic Leukemia and CML in Lymphoid Blast Crisis Patients
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.